25.02.2013 • News

Hungary's Richter Forms Joint Venture in China

Hungarian drug maker Richter has formed a joint venture to market its products more effectively in China, according to a statement posted on the web site of the Budapest stock exchange on Monday.

Richter took a 51% stake in the venture, formed with the owner of its marketing partner, Rxmidas Pharmaceuticals, and the Hungarian firm said it might take a bigger stake in the future.

Richter has said it expects sales to rise 3% on the year in euro terms in 2013 but that its operating profit margin is likely to fall, partly due to the rising cost of sales.

The joint venture will have 200 staff across 7 locations in China, Richter said, promoting the company's own prescription products and third-party prescription products.

 

Interview

Navigating Uncertainty and Driving Innovation
Meeting Pharma’s Demand for Speed, Reliability, and Flexibility

Navigating Uncertainty and Driving Innovation

Axplora CCO Arul Ramadurai discusses navigating industry uncertainty, building strategic partnerships, and advancing flexible pharmaceutical manufacturing

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.